Molecular Structure (Ef35abcf E0b6 4551 84cf A689ad11e6cd 01)
Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 63629-9155
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 63629-9155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 02)
Figure 2 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 03)
The text describes the mean change observed after different days of treatment with a placebo and Altuzosin hydrochloride extended-release tablets. There is a statistically significant difference between the two treatments. No additional information is available in the provided text.*
Figure 3 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 04)
The text represents the results of a study that compares the efficacy of a placebo and Alfuzosin hydrochloride extended-release tablets over a period of 28, 56, and 84 days. The study included 152 participants who received a placebo and 137 participants who were given Alfuzosin hydrochloride extended-release tablets. The study suggests that Alfuzosin hydrochloride extended-release tablets were significantly more effective than the placebo. However, the exact nature of the study and the specific outcomes are not mentioned in the given text.*
Figure 4 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 05)
The text seems to be presenting the results of a study evaluating the effectiveness of a drug compared to a placebo in treating a certain condition for a period of 28-56 days. The drug being tested is Altuzosin hydrochloride extended-release tablets with a sample size of 151, while the placebo has a sample size of 150. The results show a significant mean change in the condition of patients treated with the drug, as compared to those treated with the placebo over the treatment period. The text also includes a statistical significance value (p-value).*
Figure 5 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 06)
The text provides a graph showing the mean change in mL/s of placebo and alfuzosin hydrochloride extended-release tablets during 56 and 84 days of treatment. The results suggest that alfuzosin hydrochloride tablets have a significant improvement compared to the placebo.*
Figure 6 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 07)
The text describes a graph showing the mean change in milliliters per second (mL/s) over the course of a treatment measured at 0, 14, 28, 56, and 84 days. The data includes a placebo group with 147 participants and a group taking Alfuzosin hydrochloride extended-release tablets with 136 participants. The graph suggests a statistically significant difference between the two groups (p<0.05).*
Figure 7 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 08)
Company Logo (Ef35abcf E0b6 4551 84cf A689ad11e6cd 09)
Company Logo (Ef35abcf E0b6 4551 84cf A689ad11e6cd 10)
Label (Lbl636299155)
This is a description of Uroxatral 10mg Tablet packaged by Bryant Rauch Prefiack Burbiank, found at a store in zip code 91504. The recommended storage for this medication is at room temperature or between 20°C to 25°C (68°F to 77°F). The brand that produces Uroxatral 10mg Tablet is Unichem Laboratories LTD. The package contains 30 tablets and its NDC number is 6362991551 with an expiration date of MM/YY. The text also advises to keep all medications out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
